Pfizer and BioNTech Start Studies of an Omicron-Specific Vaccine

Pfizer and BioNTech announced today that they have started testing an Omicron-specific COVID-19 vaccine in healthy adults.

While data show that the current vaccine made by the companies and approved by the U.S. Food and Drug Administration continues to protect against severe disease, the vaccine is less effective at preventing infection with the virus. Studies also show that the level of immune cells generated by the vaccine wanes over time, which led the FDA to authorize a booster dose.